Share

March 28, 2023; 100 (13) Editorial

Is Soluble ST2 a Novel Biomarker of Intracerebral Hemorrhage?

Zurab Nadareishvili, Svetlana Lorenzano
First published December 22, 2022, DOI: https://doi.org/10.1212/WNL.0000000000206861
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
39

Share

Article Information

vol. 100 no. 13 599-600
DOI: 
https://doi.org/10.1212/WNL.0000000000206861
PubMed: 
36549911
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received November 24, 2022
  • Accepted in final form December 12, 2022
  • First Published December 22, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Zurab Nadareishvili, MD, PhD and
    2. Svetlana Lorenzano, MD, PhD, MSc, FESO
  1. Zurab Nadareishvili, MD, PhD and
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Svetlana Lorenzano, MD, PhD, MSc, FESO
    3. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer, travel grant for a conference (2014); (2)<br>Boehringer Ingelheim, a travel grant for a symposium <br>(2016) and a travel grant for a scientific meeting <br>(2017); 3) Quintiles IMS, a travel grant for a scientific <br>meeting (2017); 4) Daichii Sankyo, a travel grant for a <br>conference (2017).

    Editorial Boards:

    1. Neurology, member of the Editorial Board, since 2015 (no <br>compensation). <br>Only once, a compensation of $1250.00 was received from the American <br>Academy of Neurology in January 2022 for the service as one of the Editors of <br>the SVIN (Society of Vascular and Interventional Neurology) Supplement of <br>Neurology journal.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Boehringer Ingelheim (from August 2013 to July 2014, Dr. <br>Lorenzano served as expert consultant for Boehringer <br>Ingelheim)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology and Rehabilitation Medicine (Z.N.), The George Washington University School of Medicine and Health Sciences, DC; Comprehensive Stroke Center (Z.N.), VHC Health, Arlington, VA; and Department of Human Neurosciences (S.L.), Sapienza University, Rome, Italy.
  1. Correspondence
    Dr. Nadareishvili zxn5477{at}virginiahospitalcenter.com
View Full Text

Article usage

Article usage: December 2022 to April 2023

AbstractFullPdfSource
Dec 20220010Highwire
Jan 2023003Highwire
Feb 2023001Highwire
Mar 20233102615Highwire
Apr 2023145510Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me